Omics Data Generation Center (ODGC) for the Acute to Chronic Pain Signatures (A2CPS) Program - A2CPS Extension Administrative Supplement

项目摘要 慢性疼痛是一个主要的健康问题，也是成年人寻求医疗护理的最常见原因之一[1]。是 与生活质量下降、活动受限、抑郁和阿片类药物相关的大量发病率相关 依赖关系[2]。2016年，约有5000万美国成年人患有慢性疼痛，其中约有 其中40%患有高影响慢性疼痛[2]。慢性疼痛的社会成本估计为5600亿美元 每年的直接医疗费用，生产力损失和残疾计划[3]。的生物学机制 阻止急性疼痛在初始损伤后的消退，并推动从急性疼痛向慢性疼痛的转变。 知之甚少[4]。缺乏严格验证的生物标志物来预测哪些患者更容易 因此，容易从急性疼痛状态转变为慢性疼痛状态是阻碍发展的主要差距， 实施全民和个体化预防性疼痛干预措施[6]。这个的主要目标 项目是建立A2CPS组学数据生成中心（ODGC），以生成基因组变体， 代谢组学、脂质组学、蛋白质组学和exRNA数据，来自两个疼痛队列，每个队列由1800名受试者组成， 在基线、急性疼痛发作后6周和3个月收集生物流体样品。这些样品 将用于生成多组学数据，以验证40个指示易感性的主要结局生物标志物，或 对慢性疼痛发展的适应力，以及识别新的候选生物标志物。

PROJECT SUMMARY Chronic pain is a major health concern and one of the most common reasons adults seek medical care [1]. It is associated with substantial morbidity linked to reduced quality of life, restricted mobility, depression, and opioid dependence [2]. In 2016, approximately 50 million U.S. adults were afflicted with chronic pain, with approximately 40% of them having high-impact chronic pain [2]. The societal cost of chronic pain is estimated at $560 billion annually in direct medical expenses, lost productivity, and disability programs [3]. The biological mechanisms that prevent the resolution of acute pain after the initial insult and drive the transition from acute to chronic pain are poorly understood [4,5]. The lack of rigorously validated biomarkers to predict which patients are more susceptible to the transition from acute to chronic pain states is thus a major gap hindering the development and implementation of population-wide and individualized preventive pain interventions [6]. The primary goal of this project is to establish the A2CPS Omics Data Generation Center (ODGC) to generate genomic variant, metabolomic, lipidomic, proteomic, and exRNA data from two pain cohorts consisting of 1800 subjects each, with biofluid samples collected at baseline, 6 weeks, and 3 months after an acute pain episode. These samples will be used to generate multi-omic data to validate 40 primary outcome biomarkers indicating susceptibility or resilience to development of chronic pain, as well as to identify new candidate biomarkers.